



# REQUEST FOR PROPOSAL

## Investigator-sponsored trials

Investigator-sponsored trials (IST) are independent clinical or non-clinical research studies or trials initiated, sponsored and managed by researchers.

Blueprint Medicines Corporation is committed to supporting ISTs that contribute to the scientific and medical understanding of our products and relevant disease areas in order to enhance the practice of medicine and ultimately improve patient care.

All IST submissions will be critically reviewed, and a decision will be made based on scientific merit, feasibility, and our current research objectives and available resources. Proposals that directly compete with our current and/or future studies will not be considered.

### Important dates

Call for RFP — March 1, 2022

Submission deadline — May 15, 2022

Formal Selection Decisions — on or after June 15, 2022

### Questions and submissions

EMAIL

[grants@blueprintmedicines.com](mailto:grants@blueprintmedicines.com)

## EXPECTATIONS

### Submission must include:

- A full protocol, including the nature and scope of the support requested;
- A curriculum vitae (CV) or resume that documents previous clinical research experience of the proposed investigator(s) and other key research staff;
- Complete Blueprint project budget template, including itemization of costs, services and institutional fees; and
- Proposed study timelines and milestones, including a description of anticipated post-study activities and publications.

**A blind evaluation will be completed for all submitted protocols. Protocols will be scored based on six (6) criteria.**

- Alignment with areas of interest
- Scientific merit
- Contribution to the understanding of our products and/or relevant disease area
- Feasibility
- Budget
- Research completion timelines

**Funding will be provided over a period of 24 months and will be milestone-based. A final study report and draft manuscript for submission to a peer-reviewed journal will be required at the conclusion of your research.**

## AREAS OF INTEREST

**Projects that will be considered for Blueprint Medicines support will focus on the following areas:**

- Understanding the natural history of disease in systemic mastocytosis (SM), including disease worsening or progression, utilizing biomarker and clinical features to characterize risk
- Better understanding mild, moderate and severe disease in indolent SM (ISM) including the correlation of underlying biology with clinical signs and specific organ/system symptoms
- Evaluation of treatment algorithms including criteria for treatment interruptions in ISM based on objective measures

## NEXT STEPS

### To apply:

Email completed submission to [grants@blueprintmedicines.com](mailto:grants@blueprintmedicines.com)

### Approval notification:

All submissions will be reviewed by the Scientific Review Committee, and those selected will be notified on or around June 15, 2022.

### Additional information:

If interested in speaking with a Medical Affairs Representative, please email [medinfo@blueprintmedicines.com](mailto:medinfo@blueprintmedicines.com)